<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Oncotarget</journal-id>
      <journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id>
      <journal-id journal-id-type="publisher-id">Oncotarget</journal-id>
      <journal-id journal-id-type="publisher-id">ImpactJ</journal-id>
      <journal-title-group>
        <journal-title>Oncotarget</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1949-2553</issn>
      <publisher>
        <publisher-name>Impact Journals LLC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27009859</article-id>
      <article-id pub-id-type="pmc">5029658</article-id>
      <article-id pub-id-type="publisher-id">8173</article-id>
      <article-id pub-id-type="doi">10.18632/oncotarget.8173</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Amin</surname>
            <given-names>Amit Dipak</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Li</surname>
            <given-names>Lingxiao</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rajan</surname>
            <given-names>Soumya S.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gokhale</surname>
            <given-names>Vijay</given-names>
          </name>
          <xref ref-type="aff" rid="A3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="A4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Groysman</surname>
            <given-names>Matthew J.</given-names>
          </name>
          <xref ref-type="aff" rid="A5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pongtornpipat</surname>
            <given-names>Praechompoo</given-names>
          </name>
          <xref ref-type="aff" rid="A3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tapia</surname>
            <given-names>Edgar O.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Mengdie</given-names>
          </name>
          <xref ref-type="aff" rid="A6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schatz</surname>
            <given-names>Jonathan H.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><sup>1</sup> Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA</aff>
      <aff id="A2"><sup>2</sup> Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL, USA</aff>
      <aff id="A3"><sup>3</sup> BIO5 Institute, University of Arizona, Tucson, AZ, USA</aff>
      <aff id="A4"><sup>4</sup> Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA</aff>
      <aff id="A5"><sup>5</sup> Undergraduate Biology Research Program, University of Arizona, Tucson, AZ, USA</aff>
      <aff id="A6"><sup>6</sup> Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ, USA</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Jonathan H. Schatz, <email>jschatz@miami.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <day>26</day>
        <month>4</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <volume>7</volume>
      <issue>17</issue>
      <fpage>23715</fpage>
      <lpage>23729</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>5</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; 2016 Amin et al.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and acquired mutations are found in the full-length protein in the pediatric tumor neuroblastoma. ALK-specific tyrosine kinase inhibitors (TKIs) have become important new drugs for ALK-driven lung cancer, but acquired resistance via multiple mechanisms including kinase-domain mutations eventually develops, limiting median progression-free survival to less than a year. Here we assess the impact of several kinase-domain mutations that arose during TKI resistance selections of ALK+ anaplastic large-cell lymphoma (ALCL) cell lines. These include novel variants with respect to ALK-fusion cancers, R1192P and T1151M, and with respect to ALCL, F1174L and I1171S. We assess the effects of these mutations on the activity of six clinical inhibitors in independent systems engineered to depend on either the ALCL fusion kinase NPM-ALK or the lung-cancer fusion kinase EML4-ALK. Our results inform treatment strategies with a likelihood of bypassing mutations when detected in resistant patient samples and highlight differences between the effects of particular mutations on the two ALK fusions.</p>
      </abstract>
      <kwd-group>
        <kwd>anaplastic lymphoma kinase</kwd>
        <kwd>drug resistance</kwd>
        <kwd>crizotinib</kwd>
        <kwd>ceritinib</kwd>
        <kwd>alectinib</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>INTRODUCTION</title>
      <p>Anaplastic lymphoma kinase (ALK) [<xref rid="R1" ref-type="bibr">1</xref>] is an important therapeutic target in cancer, despite the function of the wild-type protein being poorly understood. While having key roles in early nervous system development [<xref rid="R2" ref-type="bibr">2</xref>], the levels of wild-type ALK subsequently drop off and remain at low levels for the remainder of life. Compounding ALK's enigmatic nature, the mammalian ligand(s) responsible for its activation are still up for debate [<xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R6" ref-type="bibr">6</xref>]. Germline and acquired mutations in wild-type ALK, however, are found in the childhood cancer neuroblastoma [<xref rid="R7" ref-type="bibr">7</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>]. Furthermore, chromosomal rearrangements fusing ALK's C-terminal kinase domain to a number of constitutively expressed genes result in malignant transformation through activation of multiple oncogenic signaling pathways [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>].</p>
      <p>In <italic>NPM-ALK</italic>, identified in 1994 [<xref rid="R13" ref-type="bibr">13</xref>], <italic>ALK</italic> is fused to the constitutively expressed nucleophosmin gene [<xref rid="R14" ref-type="bibr">14</xref>]. Approximately 70% of anaplastic large cell lymphomas (ALCL) are positive for this or similar fusions [<xref rid="R15" ref-type="bibr">15</xref>]. In fact, it was through the discovery of this fusion that <italic>ALK</italic> was originally cloned [<xref rid="R13" ref-type="bibr">13</xref>]. Subsequently, in 2007, <italic>ALK</italic> was found fused to echinoderm microtubule associated protein-like 4 (<italic>EML4</italic>) yielding the fusion kinase EML4-ALK seen in approximately 3&#x2013;5% of non-small cell lung cancers (NSCLC) [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. Several other ALK fusions since have been identified, including the <italic>RANBP2</italic> (RNA binding protein 2)-<italic>ALK</italic> fusion seen in inflammatory myofibroblastic tumor (IMT, reviewed in [<xref rid="R14" ref-type="bibr">14</xref>]).</p>
      <p>Since the highly successful use of imatinib and other BCR-ABL tyrosine kinase inhibitors (TKIs) against chronic myeloid leukemia [<xref rid="R18" ref-type="bibr">18</xref>], there have been great efforts to find inhibitors that turn off other such kinases [<xref rid="R19" ref-type="bibr">19</xref>]. In 2011, a mere four years after the discovery of EML4-ALK, the U.S. FDA approved the dual ALK/MET TKI crizotinib for ALK+ NSCLC. While initial response to crizotinib may be strong [<xref rid="R20" ref-type="bibr">20</xref>&#x2013;<xref rid="R24" ref-type="bibr">24</xref>], patients inevitably succumb due to acquired resistance through multiple mechanisms, including kinase-domain mutations, prompting development of newer generation inhibitors (Table <xref ref-type="table" rid="T1">1</xref>).</p>
      <table-wrap id="T1" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <title>Kinase domain mutations leading to acquired resistance</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th align="center" valign="top" rowspan="1" colspan="1">Cell line</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Observed mutation from this study</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Variants observed by others</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Disease observed in</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Reported resistance phenotype</th>
              <th align="center" valign="top" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle" rowspan="8" colspan="1">SUP-CR500-2</td>
              <td align="left" valign="middle" rowspan="8" colspan="1">I1171S</td>
              <td align="left" valign="middle" rowspan="2" colspan="1">I1171S</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">ASP-3026-R<sup><xref ref-type="table-fn" rid="tfn_001">*</xref></sup></td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R39" ref-type="bibr">39</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Alectinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R38" ref-type="bibr">38</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="2" colspan="1">I1171T</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-R<break/>Alectinib-R<break/>AP26113-R<break/>ASP3026-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R46" ref-type="bibr">46</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-S<break/>Alectinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R43" ref-type="bibr">43</xref>&#x2013;<xref rid="R45" ref-type="bibr">45</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="3" colspan="1">I1171N</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-R<break/>Alectinib-R<break/>AP26113-R<break/>ASP3026-S</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R41" ref-type="bibr">41</xref>, <xref rid="R42" ref-type="bibr">42</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Alectinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R45" ref-type="bibr">45</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Somatic</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R70" ref-type="bibr">70</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">I1171H</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R36" ref-type="bibr">36</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="12" colspan="1">SUP-LR150</td>
              <td align="left" valign="middle" rowspan="12" colspan="1">F1174L</td>
              <td align="left" valign="middle" rowspan="3" colspan="1">F1174L</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Alectinib-S</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R55" ref-type="bibr">55</xref>, <xref rid="R57" ref-type="bibr">57</xref>, <xref rid="R71" ref-type="bibr">71</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">RANBP2-ALK IMT</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R56" ref-type="bibr">56</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Somatic</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R7" ref-type="bibr">7</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R54" ref-type="bibr">54</xref>, <xref rid="R72" ref-type="bibr">72</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="3" colspan="1">F1174V</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-S<break/>Ceritinib-S<break/>Alectinib-R<break/>AP26113-S<break/>ASP3026-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R60" ref-type="bibr">60</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R43" ref-type="bibr">43</xref>, <xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R58" ref-type="bibr">58</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Somatic</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="3" colspan="1">F1174C</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Alectinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R46" ref-type="bibr">46</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R47" ref-type="bibr">47</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Somatic</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="2" colspan="1">F1174I</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-S<break/>Ceritnib-S<break/>Alectinib-S<break/>AP26113-S<break/>ASP3026-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R39" ref-type="bibr">39</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Somatic</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R62" ref-type="bibr">62</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">F1174S</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Somatic</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R73" ref-type="bibr">73</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="2" colspan="1">DHL1-CR500</td>
              <td align="left" valign="middle" rowspan="2" colspan="1">R1192P</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">R1192P</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Germline</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R10" ref-type="bibr">10</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">R1192Q</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Uterine leiomyosarcoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1"/>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R74" ref-type="bibr">74</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="4" colspan="1">DHL1-LR150</td>
              <td align="left" valign="middle" rowspan="4" colspan="1">T1151M</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">T1151M</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Germline</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R62" ref-type="bibr">62</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">T1151R</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Neuroblastoma</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Germline</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R75" ref-type="bibr">75</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">T1151K</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R36" ref-type="bibr">36</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">1151Tins</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-R<break/>AP26113-R<break/>ASP3026-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R58" ref-type="bibr">58</xref>, <xref rid="R61" ref-type="bibr">61</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="3" colspan="1">DHL1-CR500-2</td>
              <td align="left" valign="middle" rowspan="3" colspan="1">G1269A</td>
              <td align="left" valign="middle" rowspan="2" colspan="1">G1269A</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">NPM-ALK ALCL</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-S<break/>Alectinib-R<break/>AP26113-S<break/>ASP3026-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R64" ref-type="bibr">64</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R<break/>Ceritinib-S<break/>Alectinib-R [<xref rid="R64" ref-type="bibr">64</xref>]<break/>Alectinib-S [<xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R76" ref-type="bibr">76</xref>]<break/>AP26113-S<break/>ASP3026-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R58" ref-type="bibr">58</xref>, <xref rid="R63" ref-type="bibr">63</xref>, <xref rid="R64" ref-type="bibr">64</xref>, <xref rid="R66" ref-type="bibr">66</xref>, <xref rid="R76" ref-type="bibr">76</xref>]</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">G1269S</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">EML4-ALK NSCLC</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib-R</td>
              <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R55" ref-type="bibr">55</xref>]</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Abbreviations: ALCL = Anaplastic Large Cell Lymphoma; NSCLC = Non-Small Cell Lung Cancer; IMT = Inflammatory Myofibroblastic Tumor; R = Resistant; S = Sensitive.</p>
          <fn id="tfn_001">
            <label>*</label>
            <p>Seen by ultra-deep sequencing at low frequency.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Here we assess the resistance/sensitivity profiles of mutations that arose in patient derived-cell ALCL lines continually exposed to either crizotinib or the 2nd generation ALK/IGF-1R inhibitor ceritinib (LDK378; FDA approved in 2014 for treating ALK+ NSCLC patients who failed crizotinib) [<xref rid="R25" ref-type="bibr">25</xref>]. Each mutation was profiled against six ALK TKIs &#x2013; crizotinib, ceritinib, alectinib (which recently received FDA approval for treating ALK+ NSCLC patients who failed crizotinib [<xref rid="R26" ref-type="bibr">26</xref>]), AP26113 (brigatinib; a dual ALK/EGFR inhibitor in phase I/II trials that received FDA breakthrough therapy designation in 2014 [<xref rid="R19" ref-type="bibr">19</xref>]), ASP3026 (an ALK TKI in phase I trials [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>]) and AZD3463 (a dual ALK/EGFR inhibitor in preclinical development) [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>].</p>
    </sec>
    <sec id="s2">
      <title>RESULTS</title>
      <p>The ALK+ ALCL cell lines SUP-M2 and SU-DHL-1, which are highly sensitive to ALK inhibition (Figure <xref ref-type="fig" rid="F1">1A</xref>), were selected in increasing concentrations of either crizotinib or ceritinib to investigate mechanisms of acquired resistance. We previously showed resistance initially was caused by increased <italic>NPM-ALK</italic> expression in all of these selections, and that this ALK up-regulation induced TKI-dependency as drug withdrawal resulted in the death of resistant cells [<xref rid="R31" ref-type="bibr">31</xref>]. Individual subclones, however, were able to grow again without ALK inhibitor following prolonged passaging, leading to normalization of <italic>NPM-ALK</italic> expression. These lines were named after their respective parent lines (SUP or DHL1), the inhibitor they were grown in (CR for crizotinib resistance, LR for ceritinib (LDK378) resistance), and the top nanomolar concentration in which they were able to proliferate during selection. Despite restoration of baseline <italic>NPM-ALK</italic> expression each line still exhibited varying degrees of persistent TKI resistance. Sequencing of the ALK TKD by Sanger and deep sequencing methods had suggested second-site mutations could be driving resistance, but we did not further characterize these initial findings. For this report, we maintained resistant clones in their top TKI concentration and then twice repeated Sanger sequencing of cDNA amplified from <italic>NPM-ALK</italic> mRNA. This detected a single second-site mutation in each resistant sub-clone (Figure <xref ref-type="fig" rid="F1">1B</xref>). Two of the mutations (I1171S from SUP-CR500-2 and F1174L from SUP-LR-2) were present as single peaks in the sequencing, indicating homogeneous populations in the sub-clones following drug selections. The other three mutations (R1192P from DHL1-CR500, T1151M from DHL-LR150, and G1269A from DHL1-CR500-2) appeared together with underlying wild-type peaks, indicating heterogeneous cell populations. While some of these mutations have been observed previously in the context of ALK-fusion cancers, we characterize two novel mutations that thus far have only been observed in neuroblastoma &#x2013; T1151M and R1192P &#x2013; and two mutations not previously characterized in ALK+ ALCL (Table <xref ref-type="table" rid="T1">1</xref>). Each mutation was modeled on an X-ray structure of the ALK kinase domain (Figure <xref ref-type="fig" rid="F1">1C</xref>; discussed further below).</p>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Acquired resistance mutations in patient-derived ALK+ ALCL cell lines</title>
          <p>(<bold>A</bold>) IC50s of parental ALK+ ALCL cell lines (SUP-M2 and SU-DHL-1) as well as an ALK-negative ALCL line (MAC-2A). Mean &#xB1; SEM for quadruplicates. (<bold>B</bold>) Sanger sequencing identifying each resistance mutation in cell lines. (<bold>C</bold>) Location of the five mutations identified in this study with respect to the ALK kinase domain shown as ball and stick models with associated surfaces colored by atoms.</p>
        </caption>
        <graphic xlink:href="oncotarget-07-23715-g001"/>
      </fig>
      <p>We first compared each subclone to its respective parent line for sensitivity to the TKI in which it had been selected (Figure <xref ref-type="fig" rid="F2">2A</xref>; Table <xref ref-type="table" rid="T2">2</xref>). In all cases, subclones were significantly less sensitive, as determined by a highly significant increase in IC50, but additional factors could have arisen during selections to promote resistance. Furthermore, three of the five mutations were present in heterogeneous populations of cells also containing the wild-type NPM-ALK (as discussed above; Figure <xref ref-type="fig" rid="F1">1B</xref>). Therefore, to isolate the specific effect of each identified ALK-kinase mutation, we employed IL3-dependent FL5.12 murine pro-B cells as an independent system [<xref rid="R32" ref-type="bibr">32</xref>]. We generated each mutation through site-directed mutagenesis in <italic>NPM-ALK</italic> cloned into a GFP co-expressing MSCV-based vector (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>). Retroviral introduction of wild-type NPM-ALK or mutants, followed by IL3 withdrawal, transformed the FL5.12 cells from cytokine-dependence to oncogene-dependence (Figure <xref ref-type="fig" rid="F2">2B</xref>). Transformed lines withdrawn from IL3 proliferate only as 100% GFP+ clones, and dependence on NPM-ALK is further demonstrated by the failure of kinase-dead NPM-ALK or empty vector (not shown) to permit cytokine-independent growth. We then assessed sensitivity of lines transformed by each mutant to six TKIs in comparison to those transformed by wild-type NPM-ALK (Figure <xref ref-type="fig" rid="F2">2C</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>; Table <xref ref-type="table" rid="T3">3</xref>). All five mutations exhibited significant cross-resistance to the three approved inhibitors, crizotinib, ceritinib, and alectinib. The two mutations derived from lines that had been selected in the second-generation inhibitor ceritinib, T1151M and F1174L, were pan-resistant to all five TKIs, though degree of resistance varied (discussed below). The other three mutations, from crizotinib-selected lines, remained sensitive to at least one other inhibitor. This independent system demonstrates resistance in ALK+ ALCL lines is driven at least in part by acquired ALK kinase-domain mutations, and confirms previous observations that mutations arising in response to one drug may affect multiple inhibitors of the same target.</p>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>Resistance profiles of ALK mutations against six ALK TKIs</title>
          <p>(<bold>A</bold>) Cell viability assays (with denoted IC50s) for each resistant line compared to the parental line from which they were derived. (<bold>B</bold>) Cellular transformation of FL5.12 cells infected with an MSCV-based vector co-expressing GFP and wild-type or mutant NPM-ALK constructs upon cytokine withdrawal. The kinase-dead mutant was unable to survive in the absence of cytokine (*). (<bold>C</bold>) IC50's for each FL5.12 NPM-ALK construct against six ALK TKIs (see also <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). (<bold>D</bold>) Same as (B) but with mutations created in a retroviral vector containing EML4-ALK. (<bold>E</bold>) IC50's for each FL5.12 EML4-ALK construct against six ALK TKIs (see also <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4</xref>). Mean &#xB1; SEM for quadruplicates (A, C and E) or triplicates (B and D). (A, C and E) Unpaired two-tailed <italic>t</italic>-test was performed using GraphPad Prism version 6 to compare the IC50s for each mutant to their respective parental (A) or wild-type (C, E) cells. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.001.</p>
        </caption>
        <graphic xlink:href="oncotarget-07-23715-g002"/>
      </fig>
      <table-wrap id="T2" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <title>IC50s of each resistant line compared to the parent line from which they were derived</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th colspan="2" rowspan="3" align="left" valign="top"/>
              <th colspan="14" align="center" valign="top" rowspan="1">Cell Line</th>
            </tr>
            <tr>
              <th colspan="2" align="left" valign="top" rowspan="1">SUP-M2</th>
              <th colspan="2" align="left" valign="top" rowspan="1">SU-DHL-1</th>
              <th colspan="2" align="left" valign="top" rowspan="1">I1171S<break/>SUP-CR500-2</th>
              <th colspan="2" align="left" valign="top" rowspan="1">F1174L<break/>SUP-LR150-2</th>
              <th colspan="2" align="left" valign="top" rowspan="1">R1192P<break/>DHL1-CR500</th>
              <th colspan="2" align="left" valign="top" rowspan="1">T1151M<break/>DHL1-LR150</th>
              <th colspan="2" align="left" valign="top" rowspan="1">G1269A<break/>DHL1-CR500-2</th>
            </tr>
            <tr>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
              <th align="left" valign="top" rowspan="1" colspan="1">IC50</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Fold Change</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="2" align="left" valign="middle" colspan="1">TKI</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">67.75</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">128.9</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">878.03</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">12.96</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">887.18</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.88</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">933.275</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">7.24</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Ceritinib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">15.57</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">67.94</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">57.69</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.7</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">249.98</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.68</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">-</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T3" orientation="portrait" position="float">
        <label>Table 3</label>
        <caption>
          <title>FL5.12 NPM-ALK mutant IC50s</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th colspan="2" rowspan="3" align="left" valign="top"/>
              <th colspan="12" align="center" valign="middle" rowspan="1">FL5.12 NPM-ALK</th>
            </tr>
            <tr>
              <th colspan="2" align="center" valign="middle" rowspan="1">WT</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">I1171S</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">F1174L</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">R1192P</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">T1151M</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">G1269A</th>
            </tr>
            <tr>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="6" align="left" valign="middle" colspan="1">TKI</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">171.85</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">345.03</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.01</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">347.63</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.02</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">421.5</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.45</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">346.65</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.02</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">871.75</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.07</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Ceritnib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">34.03</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">75.8</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.23</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">140.45</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.13</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">167.08</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.91</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">95.78</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.81</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">46.04</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.35</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Alectinib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">11.13</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">192.5</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">17.29</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">46.43</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.17</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">48.84</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.39</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">25.42</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.28</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">89.27</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">8.02</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To further identify the potential clinical implications of each mutation, and to assess whether the effects of each mutation are fusion-specific, we employed an additional <italic>in vitro</italic> model. Each mutation was generated via site-directed mutagenesis in <italic>EML4-ALK</italic>, the most common ALK fusion detected in NSCLC, and cloned into the same GFP-expressing MSCV-based vector backbone described above (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S3</xref>). Once again, using FL5.12 murine pro-B cells, retroviral introduction of each <italic>EML4-ALK</italic> mutant construct and subsequent IL3 withdrawal resulted in cytokine-independent, oncogene-dependent cellular transformation (Figure <xref ref-type="fig" rid="F2">2D</xref>). The resistance/sensitivity profiles of each <italic>EML4-ALK</italic> mutant versus wild-type <italic>EML4-ALK</italic> to the same panel of TKIs were assessed in the same manner as above (Figure <xref ref-type="fig" rid="F2">2E</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4</xref>; Table <xref ref-type="table" rid="T4">4</xref>). For mutations previously observed in ALK TKI resistance models, our results were largely consistent with individual findings reported by others (Table <xref ref-type="table" rid="T1">1</xref>). We observed some important differences, however, between the effects of particular mutations on NPM-ALK vs. EML4-ALK (compare Figure <xref ref-type="fig" rid="F2">2E</xref> and Figure <xref ref-type="fig" rid="F2">2C</xref>). In particular, R1192P and T1151M &#x2013; never before detected in resistant EML4-ALK-driven cell lines or patient samples &#x2013; had substantially greater effect on NPM-ALK in promoting resistance than on EML4-ALK. These findings among others highlight potentially clinically important differences mediated by ALK's fusion partner affecting selection by tumors for particular mutations (see discussion).</p>
      <table-wrap id="T4" orientation="portrait" position="float">
        <label>Table 4</label>
        <caption>
          <title>FL5.12 EML4-ALK mutant IC50s</title>
        </caption>
        <table frame="box" rules="all">
          <thead>
            <tr>
              <th colspan="2" rowspan="3" align="center" valign="top"/>
              <th colspan="12" align="center" valign="middle" rowspan="1">FL5.12 EML4-ALK</th>
            </tr>
            <tr>
              <th colspan="2" align="center" valign="middle" rowspan="1">WT</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">I1171S</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">F1174L</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">R1192P</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">T1151M</th>
              <th colspan="2" align="center" valign="middle" rowspan="1">G1269A</th>
            </tr>
            <tr>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">IC50</th>
              <th align="center" valign="middle" rowspan="1" colspan="1">Fold Change</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="6" align="left" valign="middle" colspan="1">TKI</td>
              <td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">70.59</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">260.38</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.7</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">68.14</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.97</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">86.27</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.25</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">89.07</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.27</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">395.2</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.62</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Ceritnib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">9.6</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">64.69</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.79</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">16.86</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.76</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">16.96</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.79</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">24.24</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.53</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">14.57</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.52</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">Alectinib</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.46</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">224.28</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">64.98</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.35</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.98</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.55</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.70</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.00</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.87</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">40.09</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">11.6</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">AP26113</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.13</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">24.87</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">6.09</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.79</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.42</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.7</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.66</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">3.81</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.93</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">4.4</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.08</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">ASP3026</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">42.21</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">245.13</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">5.83</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">110.97</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.63</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">90.59</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.11</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">105.73</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.51</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">71.79</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.71</td>
            </tr>
            <tr>
              <td align="left" valign="middle" rowspan="1" colspan="1">AZD3463</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">16.79</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">38.27</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">2.28</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">15.83</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.94</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">10.16</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.59</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">18.99</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">1.13</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">11.62</td>
              <td align="center" valign="middle" rowspan="1" colspan="1">0.69</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>We next assessed through immunoblotting the signaling consequences in FL5.12 cells of NPM-ALK-R1192P and T1151M, the two mutations not previously described as fusion ALK-kinase resistance mutations (Figure <xref ref-type="fig" rid="F3">3</xref>). Results suggest a particularly strong resistance phenotype of R1192P to all the inhibitors except AP26113, in line with the IC50 data. The effect of T1151M, meanwhile, was weaker, with higher concentrations of all drugs except ASP3026 overcoming its effects on ALK phosphorylation. We note that pERK levels decreased in crizotinib-treated FL5.12 cells not transfected with NPM-ALK (growing in IL3), and pERK is correspondingly more crizotinib sensitive in all the transformed lines as well. This suggests an off-target effect such as this drug's known activity against MET [<xref rid="R33" ref-type="bibr">33</xref>]. Similar to our published findings, phosphorylation of ERK and AKT were overall variable in these results, providing inconsistent markers of drug potency [<xref rid="R31" ref-type="bibr">31</xref>]. STAT3 activation, however, (indicated by phosphorylation at Y705), which is known to be ALCL's core survival pathway was strongly consistent with drug potency and ALK phosphorylation status [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>]. We therefore confirm drug-resistant ALK activation promoting ALCL's core survival pathway mediated by NPM-ALK-R1192P and T1151M, consistent with viability data.</p>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Activated ALK and downstream signaling is preserved in the novel ALK-fusion mutations, R1192P and T1151M</title>
          <p>Immunoblotting for ALK and downstream signaling targets at the indicated concentrations of six ALK TKIs for FL5.12 cells (A), FL5.12 cells infected with an MSCV-based vector co-expressing GFP and wild-type NPM-ALK (B), NPM-ALK R1192P (C) or NPM-ALK T1151M (D).</p>
        </caption>
        <graphic xlink:href="oncotarget-07-23715-g003"/>
      </fig>
    </sec>
    <sec id="s3">
      <title>DISCUSSION</title>
      <p>Resistance to ALK-kinase inhibition in lung cancer is described in several published studies that employed cell lines, patient samples, or both. Our goal has been to understand resistance in ALK+ ALCL, which is less well studied. We previously reported resistance driven by <italic>NPM-ALK</italic> up-regulation, which also paradoxically drives dependence on continued inhibitor exposure, defining for the first time oncogene overdose by ALK over-activation [<xref rid="R31" ref-type="bibr">31</xref>]. Here, we examine five <italic>NPM-ALK</italic> kinase domain mutations that drive resistance in ALCL in an absence of over-expression. Two of these, R1192P and T1151M, are previously unreported as ALK TKI resistance mutations. We evaluated mutations in an independent system permitting isolation of mutation effect from other factors that may arise in ALK-dependent cells continually exposed to inhibitors. These experiments showed R1192P, T1151M, and the other mutations in <italic>NPM-ALK</italic> adversely affected the activity of multiple ALK TKIs but also pointed to inhibitors for which sensitivity is maintained or even enhanced. Interestingly, cross-validation using the lung cancer-derived <italic>EML4-ALK</italic> fusion showed both similarities and key differences in the effect of mutations on particular drugs. Our study therefore characterizes novel <italic>NPM-ALK</italic> TKI resistance mutations, providing guidance for appropriate choice of alternate therapies as more of these drugs move toward regulatory approval. It also highlights key differences in the effect of mutations on the ALK kinase domain's sensitivity to inhibition depending on its fusion partner. For example, the fact that R1192P and T1151M have not previously been detected in resistant EML4-ALK-driven systems is not surprising since their effect on drug activity was significantly less for that kinase than for NPM-ALK. The profile of ALK TKI resistance mutations likely to arise in a tumor, therefore, is inherently shaped by ALK's fusion partner, as should choices of alternative therapy.</p>
      <sec id="s3_1">
        <title>I1171S</title>
        <p>I1171S previously was seen in an <italic>in vitro</italic> accelerated mutagenesis screen in ALK+ NSCLC using increasing concentrations of crizotinib [<xref rid="R36" ref-type="bibr">36</xref>] and somatic mutations in this residue also have been reported in neuroblastoma [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>]. Subsequently, this mutation was identified in an ALK+ NSCLC patient as conferring alectinib resistance [<xref rid="R38" ref-type="bibr">38</xref>]. Consistent with its original identification in EML4-ALK-driven systems, we find I1171S is potently resistance-conferring to FL5.12 cells dependent on this fusion. All six TKIs tested had significantly increased IC50s when tested vs. EML4-ALK-I117S compared to wild-type (Figure <xref ref-type="fig" rid="F2">2E</xref>). In NPM-ALK, I1171S promoted resistance to crizotinib, the drug used in selecting the line in which it was isolated, ceritinib, and again pronounced resistance to alectinib. Ultra-deep sequencing previously identified I1171S at very low frequencies as a candidate ASP3026-resistant mutation in ALK+ ALCL [<xref rid="R39" ref-type="bibr">39</xref>], which is also confirmed in our functional system. Interestingly, however, NPM-ALK-I1171S promoted no resistance, indeed increased sensitivity compared to wild type, to both AP26113 and AZD3463. The effect of a resistance mutation conferring sensitivity to other inhibitors is similar to a recent high-profile case report in which the L1198F mutation, providing resistance to the third-generation inhibitor lorlatinib, resulted in resensitization to crizotinib [<xref rid="R40" ref-type="bibr">40</xref>]. The novel finding in our study is that this effect was seen for NPM-ALK but not EML4-ALK. Our data do not identify the reason for differential the effects of I1171S on AP26113 and AZD3463 (structurally similar compounds that also inhibit EGFR) between NPM-ALK and EML4-ALK. Given the FL5.12 system used is identical in all ways other than ALK's fusion partner, the effect is likely on-target, mediated by subtle ATP binding-pocket differences between the two fusion kinases.</p>
        <p>Several other amino acid substitutions occur at I1171 residue, all promoting resistance to both crizotinib and alectinib regardless of whether their characterization was in the context of NSCLC or ALCL (Table <xref ref-type="table" rid="T1">1</xref>) [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R41" ref-type="bibr">41</xref>&#x2013;<xref rid="R46" ref-type="bibr">46</xref>]. There are some differences in TKI resistance between our findings for I1171S and other amino acid substitutions at this residue. For instance, in lymphoma studies, I1171N and I1171T are reported to be AP26113-resistant [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R41" ref-type="bibr">41</xref>], and while both appear resistant to ceritinib in NPM-ALK [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R41" ref-type="bibr">41</xref>], they show sensitivity in EML4-ALK [<xref rid="R43" ref-type="bibr">43</xref>, <xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>]. Further variability exists for both I1171N and I1171T, with the former being ASP3026-sensitive [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R42" ref-type="bibr">42</xref>] and the latter resistant [<xref rid="R39" ref-type="bibr">39</xref>] in NPM-ALK.</p>
        <p>I1171 is part of the hydrophobic regulatory spine (R-spine), along with residues C1182, F1271 (DFG motif), H1247 (HRD motif) and D1311 (F-helix), which connects the two major ALK TKD lobes. Mutations in I1171 are believed to lock ALK in its active conformation, accelerating its activation through autophosphorylation [<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R43" ref-type="bibr">43</xref>, <xref rid="R49" ref-type="bibr">49</xref>&#x2013;<xref rid="R52" ref-type="bibr">52</xref>]. Additionally, mutations at this residue decrease stability of inhibitor binding at the DFG motif, and, in the case of at least I1171N, modify the structure of the kinase-inhibitor complex [<xref rid="R41" ref-type="bibr">41</xref>]. Our data suggest NPM-ALK+ ALCL patients who develop resistance due to I1171S could benefit from treatment using either AP26113 or AZD3463, as both overcome this mutation in our independent system. Other inhibitors may be necessary in the context of EML4-ALK.</p>
      </sec>
      <sec id="s3_2">
        <title>F1174L</title>
        <p>The phenylalanine residue at position 1174, located at the end of the &#x3B1;C helix amongst a highly hydrophobic cluster of residues, maintains autoinhibitory interactions when ALK is in its inactive conformation [<xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R49" ref-type="bibr">49</xref>, <xref rid="R51" ref-type="bibr">51</xref>] and is a mutational hotspot within the ALK kinase domain [<xref rid="R53" ref-type="bibr">53</xref>]. We found F1174L in a cell line grown in increasing concentrations of ceritinib. It is a frequent somatic mutation in neuroblastoma and increases ALK's affinity for ATP, despite not directly contacting the ATP pocket. Accordingly, resistance is not due to steric hindrance of drug binding, but rather promotion of ALK's active conformation indicated by accelerated autophosphorylation [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R54" ref-type="bibr">54</xref>]. F1174L therefore acts as both a TKI-resistance and an activating mutation [<xref rid="R7" ref-type="bibr">7</xref>&#x2013;<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R37" ref-type="bibr">37</xref>, <xref rid="R54" ref-type="bibr">54</xref>]. In agreement with our observations for NPM-ALK (Table <xref ref-type="table" rid="T1">1</xref>; Figure <xref ref-type="fig" rid="F2">2C</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>), F1174L results in resistance to crizotinib in both ALK+ NSCLC and ALK+ IMT [<xref rid="R55" ref-type="bibr">55</xref>&#x2013;<xref rid="R57" ref-type="bibr">57</xref>], although we did not observe a significant change in resistance in our EML4-ALK <italic>in vitro</italic> assay (<italic>p</italic> = 0.4846; Table <xref ref-type="table" rid="T4">4</xref>; Figure <xref ref-type="fig" rid="F2">2E</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4</xref>). In contrast to previous reports in ALK+ NSCLC [<xref rid="R56" ref-type="bibr">56</xref>&#x2013;<xref rid="R58" ref-type="bibr">58</xref>] along with our EML4-ALK <italic>in vitro</italic> assay, we observe resistance to alectinib, which is more in agreement with this mutation favoring ATP binding over inhibitor binding, and suggests potential differences in the conformational changes induced by a leucine substitution at this residue based on ALK's fusion partner. Studies involving other amino acid substitutions at position 1174 support this. Whereas F1174C and F1174V are resistant to crizotinib and ceritinib in ALK+ NSCLC cell line models and patient samples [<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R59" ref-type="bibr">59</xref>], F1174V and F1174I are sensitive to both TKIs in ALK+ ALCL [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R60" ref-type="bibr">60</xref>].</p>
        <p>Furthermore, despite F1174C and F1174V showing resistance to alectinib in ALK+ ALCL [<xref rid="R46" ref-type="bibr">46</xref>, <xref rid="R60" ref-type="bibr">60</xref>], this drug is able to overcome an isoleucine substitution in the same model [<xref rid="R39" ref-type="bibr">39</xref>]. Additionally, while we observe a small fold-increase in the IC50 for AP26113 (1.4-fold) for this mutant compared to wild-type NPM-ALK, the increase is not statistically significant (<italic>p</italic> = 0.0513), and AP26113 has been reported to show sensitivity to both F1174V and F1174I [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R60" ref-type="bibr">60</xref>]. Our data for both fusions, in agreement with other studies in NPM-ALK, show ASP2036 is unable to overcome any amino acid substitutions at this location [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R60" ref-type="bibr">60</xref>]. Furthermore, while AP26113 may show slight efficacy in overcoming ALK+ ALCL resistance acquired by this mutation (<italic>p</italic> = 0.0513), it is predicted to be ineffective in ALK+ NSCLC, with the opposite being true for AZD3463 with respect to each disease. This further highlights the care required when considering treatment options to overcome resistance in patients, as both the specific substitution and the particular ALK-fusion may be key factors.</p>
      </sec>
      <sec id="s3_3">
        <title>R1192P</title>
        <p>The R1192P mutation, residing in the N-lobe, is one of the most frequent germline mutations in neuroblastoma [<xref rid="R10" ref-type="bibr">10</xref>]. In a similar fashion to both I1171 and F1174 mutations, R1192P results in accelerated autophosphorylation of ALK's TKD [<xref rid="R37" ref-type="bibr">37</xref>]. In fact, this mutation is considered an exception, as most residues in the N-lobe have smaller impacts. We report here for the first time the identification of this mutation in any ALK-fusion cancer, in a cell line selected in crizotinib. Perhaps unsurprisingly, due to its ability to strongly turn on the kinase activity of ALK, all but one TKI proved to be ineffective at overcoming resistance to this mutation in NPM-ALK (Table <xref ref-type="table" rid="T1">1</xref>; Figures <xref ref-type="fig" rid="F2">2C, 2D</xref> and <xref ref-type="fig" rid="F3">3</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). The only exception, AP26113, may be an attractive therapeutic in the event of resistance by this mutation. The effect of this mutation was dramatically less vs. all drugs when it was introduced instead to EML4-ALK, likely explaining, as discussed above, why it has never been reported in resistant ALK+ lung cancer. Detailed structural determinations are outside the scope of this report, but it is interesting to note that all three mutations reported to activate ALK kinase rather than block drug binding to the ATP pocket &#x2013; F1174L, R1192P, and T1151M (below) &#x2013; have greater effect on drug activity when found in NPM-ALK than in EML4-ALK. Follow-up structural chemistry studies to this report may confirm and identify the basis for this effect.</p>
      </sec>
      <sec id="s3_4">
        <title>T1151M</title>
        <p>T1151M was identified recently in neuroblastoma patients [<xref rid="R37" ref-type="bibr">37</xref>] and we present here the first report of this mutation in the ALK-fusion context, arising in a cell line grown in ceritinib. An amino acid insertion, 1151T<italic>ins</italic> is well-characterized as causing cross-resistance to several ALK TKIs in ALK+ NSCLC cell lines and patients [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R61" ref-type="bibr">61</xref>], although one study reports that alectinib is effective against it [<xref rid="R58" ref-type="bibr">58</xref>]. Additionally, 1151T<italic>ins</italic> was reported in neuroblastoma [<xref rid="R62" ref-type="bibr">62</xref>]. Finally, the amino acid substitution T1151K was also found in an accelerated mutagenesis screen in ALK+ NSCLC assessing crizotinib resistance [<xref rid="R36" ref-type="bibr">36</xref>].</p>
        <p>Mutations at residue 1151, located at the N-terminal lobe of the ALK catalytic domain, alter affinity of the mutated kinase for ATP, and diminish inhibitor binding through conformational changes, despite lying some distance from the ATP pocket [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R61" ref-type="bibr">61</xref>]. Furthermore, mutations in this domain lead to activation of the ALK TKD, albeit more modestly than I1171, F1174, or R1192 [<xref rid="R37" ref-type="bibr">37</xref>]. It is therefore perhaps unsurprising that 1151T<italic>ins</italic>, T1151K, or, in our case, T1151M in NPM-ALK, cause cross-resistance to several ALK TKIs due to the mutant kinase domain strongly favoring ATP binding, as confirmed by fold-changes in IC50 and western blotting (Table <xref ref-type="table" rid="T1">1</xref>; Figure <xref ref-type="fig" rid="F2">2C</xref> and <xref ref-type="fig" rid="F2">2D</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). Somewhat surprising is the lack of significant change in response to AP26113 (<italic>p</italic> = 0.2090) and sensitivity to alectinib (<italic>p</italic> = 0.0169; in agreement with Kodama et al. [<xref rid="R58" ref-type="bibr">58</xref>] as mentioned above) when compared to wild-type EML4-ALK, further highlighted the importance of the particular amino acid substitution, as well as the potential differences in protein folding dependent upon the fusion partner in question.</p>
      </sec>
      <sec id="s3_5">
        <title>G1269A</title>
        <p>In agreement with our observations, this mutation resists crizotinib in both NPM-ALK (as expected as it was isolated from a cell line grown in crizotinib) and EML4-ALK, but is sensitive to AP26113 in both fusions [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R63" ref-type="bibr">63</xref>, <xref rid="R64" ref-type="bibr">64</xref>]. A serine substitution at the same residue behaves similarly in EML4-ALK [<xref rid="R36" ref-type="bibr">36</xref>, <xref rid="R55" ref-type="bibr">55</xref>]. G1269 lies in the ATP-binding pocket, making direct contact with crizotinib. Using computer modeling (Figure <xref ref-type="fig" rid="F1">1C</xref>), we observed that the dichlorofluorophenyl ring of crizotinib binds near G1269 (distance 3.49 &#xC5; between Ca G1269 and fluorine atom). G1269A causes a steric clash between the dichlorofluorophenyl ring and the alanine's methyl group, apparently sufficient to disrupt the drug's activities [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R63" ref-type="bibr">63</xref>, <xref rid="R65" ref-type="bibr">65</xref>]. Much like T1151 mutations, G1269 mutations cause modest constitutive ALK tyrosine kinase activity [<xref rid="R37" ref-type="bibr">37</xref>].</p>
        <p>While we observed resistance to ceritinib in both fusions (Table <xref ref-type="table" rid="T1">1</xref>; Figure <xref ref-type="fig" rid="F2">2C</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>), others have shown that ceritinib effectively overcomes G1269A in both ALK+ NSCLC [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R47" ref-type="bibr">47</xref>] and ALK+ ALCL [<xref rid="R64" ref-type="bibr">64</xref>] due to it stabilizing ALK's conformational dynamics and exhibiting increased potency for this mutant over WT ALK [<xref rid="R48" ref-type="bibr">48</xref>]. Once again, the degree of resistance in our study was only mild (1.35-fold for NPM-ALK and 1.52-fold for EML4-ALK), albeit still statistically significant (<italic>p</italic> = 0.0018 and &lt; 0.0001, respectively), which may explain this difference. Another discrepancy is with ASP3026, predicted to overcome resistance in NPM-ALK by our data but unable to do so in a separate study in both ALK+ NSCLC and ALK+ ALCL [<xref rid="R64" ref-type="bibr">64</xref>]. However, the sensitivity reported in our study is just barely significant (<italic>p</italic> = 0.0495), perhaps explaining this discrepancy. Additionally, while we and Fontana and colleagues [<xref rid="R64" ref-type="bibr">64</xref>] report that alectinib is unable to overcome G1269A in the context of either disease, two other studies showed a response to alectinib <italic>in vitro</italic>, in xenograft models, and in a patient harboring this mutation [<xref rid="R58" ref-type="bibr">58</xref>, <xref rid="R66" ref-type="bibr">66</xref>]. Borderline results <italic>in vitro</italic> may therefore be less reliable predictors of responses <italic>in vivo</italic>. Indeed, others have shown some TKIs with IC50 shifts <italic>in vitro</italic> may still cause tumor regression <italic>in vivo</italic> [<xref rid="R47" ref-type="bibr">47</xref>]. Further trial and error, including studies in resistant patients, will be necessary to clarify the situation for some mutations. Our data suggest AZD3463 may be able to overcome G1269A in both fusion-cancers. Both ASP3026 and AZD3463 interact differently compared to crizotinib with the active site near G1269. The X-ray crystal structure of ASP3026 with the ALK kinase domain (PDB code: 2XB7) shows that the isopropylsulfone group interacts with lysine 1150 through hydrogen bonding. This bond draws ASP3026's binding away from G1269 (distance = 5.85 &#xC5; between G1269 Ca and methylene carbon), and it is expected that ASP3026 would bind G1269A mutant in similar fashion.</p>
        <p>The ALK kinase has several mutational hotspots, such as F1174, F1245 and R1275 [<xref rid="R53" ref-type="bibr">53</xref>]. The identification of two mutations not previously reported in any malignancy driven by an ALK-fusion (T1151M and R1192P) is therefore highly informative. Despite a predilection for certain mutations conferring resistance, &#x201C;novel&#x201D; mutations at sites other than mutational hotspots can still occur, perhaps albeit at lower frequencies, as the tumor evolves in a desperate attempt to evade death. Our findings with mutations favoring ATP-binding and dampening inhibitor-binding and/or constitutively activating ALK's TKD, suggest newer competitive inhibitors are desperately needed to overcome acquired resistance. One such inhibitor, the first 3rd generation ALK (and ROS1) inhibitor PF-06463922 (lorlatinib), exhibits increased potency against F1174L, 1151Tins, I1171T and G1269A in preclinical EML4-ALK models [<xref rid="R67" ref-type="bibr">67</xref>, <xref rid="R68" ref-type="bibr">68</xref>], with impressive anti-tumour activity observed in xenograft neuroblastoma models harboring F1174L [<xref rid="R53" ref-type="bibr">53</xref>]. Another new inhibitor, a structural analog of alectinib, JH-VIII-157-02, also shows great promise against a series of ALK resistance mutations, including G1269A, F1174L and 1151Tins [<xref rid="R69" ref-type="bibr">69</xref>]. Further development and screening of newer generation ALK inhibitors is highly important in overcoming resistance mutations in patients suffering from ALK-related malignancies.</p>
      </sec>
    </sec>
    <sec sec-type="methods" id="s4">
      <title>MATERIALS AND METHODS</title>
      <sec id="s4_1">
        <title>Cell lines, reagents and inhibitors</title>
        <p>RPMI 1640 and penicillin/streptomycin (P/S) supplemented with 10% fetal bovine serum (FBS) for SU-DHL-1 and MAC 2A, or with 20% FBS for SUP-M2. Phoenix cells grown in DMEM plus 10% FBS and P/S. FL5.12 cells cultured in RPMI 1640 with 10% FBS, P/S, &#xB1; 10% WeHi-3B supernatant and murine IL3 (400 &#x3C1;M, eBioscience). All lines purchased from DSMZ apart from FL5.12's (gift from Wendel lab). Crizotinib and alectinib were purchased from Selleck Chemicals; ceritinib (LDK378) was kindly provided by Novartis.</p>
      </sec>
      <sec id="s4_2">
        <title>Cell viability assays</title>
        <p>3000 cells per well were seeded in serial dilutions of the indicated ALK TKIs. Viability was assessed after 72 hours (Cell Titer Glo<sup>&#xAE;</sup>; Promega) by measuring luminescence on a BioTek Synergy HT plate reader. GraphPad Prism version 6 was used to calculate IC50s with non-linear curve-fit regression.</p>
      </sec>
      <sec id="s4_3">
        <title>Computer modeling</title>
        <p>Images in Figure <xref ref-type="fig" rid="F1">1C</xref> were created using the X-ray structure of ALK kinase domain using the Maestro software (Schrodinger Inc.)</p>
      </sec>
      <sec id="s4_4">
        <title>Identification of kinase-domain mutations</title>
        <p>RNA extraction (RNeasy<sup>&#xAE;</sup> Mini Ki; QIAgen) followed by cDNA synthesis (Taqman<sup>&#xAE;</sup> Reverse Transcriptase kit; Roche) was carried out two independent times for all resistant cell lines as well as their respective parental lines. The NPM-ALK fusion was PCR amplified (Primers - Forward: GTCCGCCTTCTCTCCTACCT, Reverse: TTGGCACAAAACAAAACGTG) on a BioRad T100 Thermal Cycler. The kinase domain was sequenced by Sanger sequencing. The sequences obtained for the resistant lines were aligned to their respective parental lines using the ClustalW online sequence alignment tool to identify base pair changes. The identified mutations were the same for both independent sets of sequencing.</p>
      </sec>
      <sec id="s4_5">
        <title>Protein extraction, quantification and immunoblotting</title>
        <p>As described previously [<xref rid="R31" ref-type="bibr">31</xref>], loading 30 &#x3BC;g per lane, with all primary and secondary antibodies from Cell Signal Technology, developed using autoradiograph film (GeneMate).</p>
      </sec>
      <sec id="s4_6">
        <title>Site directed mutagenesis</title>
        <p>Plasmid purification (PerfectPrep Spin Mini Kit; 5Prime) was carried out for MSCV-based -NPM-ALK and -EML4-ALK vectors mutated using site directed mutagenesis (QuikChange II XL; Agilent Technologies). Sanger sequencing was then used to confirm the presence of mutations in the ALK TKD.</p>
      </sec>
      <sec id="s4_7">
        <title>Transfections, infections and cellular transformation</title>
        <p>As described previously [<xref rid="R31" ref-type="bibr">31</xref>] using an MSCV-based vector co-expressing GFP plus either wild-type NPM-ALK, wild-type EML4-ALK, each NPM-ALK mutation, the same mutations in EML4-ALK, or an NPM-ALK kinase dead mutation (K210R) as a negative control. Cellular transformation was assessed by flow cytometry (Guava EasyCyte).</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="s5">
      <title>SUPPLEMENTARY MATERIALS FIGURES</title>
      <supplementary-material content-type="local-data" id="SD1">
        <media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-07-23715-s001.pdf" orientation="portrait" xlink:type="simple" id="d36e2102" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>The MIG-NPM-ALK and MIG-NPM-ALK-Kd plasmids were generously provided by Dr. Emanuela Colombo (University of Milano, Milan, Italy). The pCDH1-MCS1-EML4-ALKv3-EF1-Puro plasmid was a generous gift from Dr. Robert Doebele (University of Colorado, USA). Custom DNA Constructs (Ohio, USA) cloned the EML4-ALK ORF into the MSCV-backbone.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>
          <bold>CONFLICTS OF INTEREST</bold>
        </p>
        <p>The authors declare no conflicts of interest.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>
          <bold>GRANT SUPPORT</bold>
        </p>
        <p>This work was supported by the NIH/NCGI grant 1R01CA190696-01 awarded to JHS.</p>
      </fn>
      <fn fn-type="con">
        <p>
          <bold>Authors' contributions</bold>
        </p>
        <p>Conceived and designed the experiments: ADA and JHS; Performed the experiments: ADA, LL, SSR, VG, MJG, PP, EOT and MW; Analyzed the data: ADA, LL, SSR, VG, MJG, PP, EOT, MW and JHS; Wrote the paper: ADA and JHS.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hallberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology</article-title>
          <source>Nat Rev Cancer</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>685</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="pmid">24060861</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamant</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pulford</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bischof</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Delsol</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mariame</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Expression of the ALK tyrosine kinase gene in neuroblastoma</article-title>
          <source>Am J Pathol</source>
          <year>2000</year>
          <volume>156</volume>
          <fpage>1711</fpage>
          <lpage>1721</lpage>
          <pub-id pub-id-type="pmid">10793082</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Umapathy</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wolfstetter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mendoza</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pfeifer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mohammed</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hugosson</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Halenbeck</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hallberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>FAM150A and FAM150B are activating ligands for Anaplastic Lymphoma Kinase</article-title>
          <source>Elife</source>
          <year>2015</year>
          <volume>4</volume>
          <fpage>e09811</fpage>
          <pub-id pub-id-type="pmid">26418745</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Lax</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Reshetnyak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ligon</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Lillquist</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Natoli</surname>
              <given-names>EJ</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Folta-Stogniew</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gunel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alvarado</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schlessinger</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK</article-title>
          <source>Sci Signal</source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>ra6</fpage>
          <pub-id pub-id-type="pmid">25605972</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoica</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aigner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sunitha</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Souttou</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Malerczyk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Caughey</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Karavanov</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Riegel</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Wellstein</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>16772</fpage>
          <lpage>16779</lpage>
          <pub-id pub-id-type="pmid">11278720</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoica</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bowden</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Sale</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Riegel</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Wellstein</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types</article-title>
          <source>J Biol Chem</source>
          <year>2002</year>
          <volume>277</volume>
          <fpage>35990</fpage>
          <lpage>35998</lpage>
          <pub-id pub-id-type="pmid">12122009</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takita</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ohira</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sanada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Soda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Igarashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakagawara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mano</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oncogenic mutations of ALK kinase in neuroblastoma</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>455</volume>
          <fpage>971</fpage>
          <lpage>974</lpage>
          <pub-id pub-id-type="pmid">18923524</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Sanda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hanna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frohling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Luther</surname>
              <given-names>W</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>London</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>McGrady</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zozulya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gregor</surname>
              <given-names>VE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activating mutations in ALK provide a therapeutic target in neuroblastoma</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>455</volume>
          <fpage>975</fpage>
          <lpage>978</lpage>
          <pub-id pub-id-type="pmid">18923525</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janoueix-Lerosey</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lequin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brugieres</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Pontual</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Combaret</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Raynal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Puisieux</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schleiermacher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pierron</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Valteau-Couanet</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Frebourg</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Michon</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>455</volume>
          <fpage>967</fpage>
          <lpage>970</lpage>
          <pub-id pub-id-type="pmid">18923523</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moss&#xE9;</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Laudenslager</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Longo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Attiyeh</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Laquaglia</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sennett</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Perri</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laureys</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Speleman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of ALK as a major familial neuroblastoma predisposition gene</article-title>
          <source>Nature</source>
          <year>2008</year>
          <volume>455</volume>
          <fpage>930</fpage>
          <lpage>935</lpage>
          <pub-id pub-id-type="pmid">18724359</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiarle</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Voena</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ambrogio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Piva</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Inghirami</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The anaplastic lymphoma kinase in the pathogenesis of cancer</article-title>
          <source>Nat Rev Cancer</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>11</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">18097461</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Webb</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Slavish</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Look</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Rentrop</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</article-title>
          <source>Expert Rev Anticancer Ther</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>331</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="pmid">19275511</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morris</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Kirstein</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Valentine</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Dittmer</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Saltman</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Look</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</article-title>
          <source>Science</source>
          <year>1994</year>
          <volume>263</volume>
          <fpage>1281</fpage>
          <lpage>1284</lpage>
          <pub-id pub-id-type="pmid">8122112</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearson</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Bacani</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ingham</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases</article-title>
          <source>J Signal Transduct</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>123253</fpage>
          <pub-id pub-id-type="pmid">22852078</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreri</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Govi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Savage</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Anaplastic large cell lymphoma, ALK-positive</article-title>
          <source>Crit Rev Oncol Hematol</source>
          <year>2012</year>
          <volume>83</volume>
          <fpage>293</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">22440390</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rikova</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Possemato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haack</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nardone</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Reeves</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Stokes</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</article-title>
          <source>Cell</source>
          <year>2007</year>
          <volume>131</volume>
          <fpage>1190</fpage>
          <lpage>1203</lpage>
          <pub-id pub-id-type="pmid">18083107</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Enomoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kurashina</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hatanaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bando</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>448</volume>
          <fpage>561</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="pmid">17625570</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moen</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>McKeage</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Plosker</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Imatinib: a review of its use in chronic myeloid leukaemia</article-title>
          <source>Drugs</source>
          <year>2007</year>
          <volume>67</volume>
          <fpage>299</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">17284091</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iragavarapu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mustafa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Akinleye</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Furqan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mittal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Cang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Novel ALK inhibitors in clinical use and development</article-title>
          <source>J Hematol Oncol</source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>17</fpage>
          <pub-id pub-id-type="pmid">25888090</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bang</surname>
              <given-names>YJ</given-names>
            </name>
          </person-group>
          <article-title>The potential for crizotinib in non-small cell lung cancer: a perspective review</article-title>
          <source>Ther Adv Med Oncol</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>279</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="pmid">22084642</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camidge</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Kwak</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Iafrate</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Varella-Garcia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Riely</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ou</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Salgia</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fidias</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</article-title>
          <source>Lancet Oncol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>1011</fpage>
          <lpage>1019</lpage>
          <pub-id pub-id-type="pmid">22954507</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwak</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Camidge</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Maki</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Ou</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Dezube</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Janne</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Varella-Garcia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>TJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>1693</fpage>
          <lpage>1703</lpage>
          <pub-id pub-id-type="pmid">20979469</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moss&#xE9;</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Voss</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Wilner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ruffner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Laliberte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rolland</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Balis</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Maris</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Weigel</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Ingle</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Ahern</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Adamson</surname>
              <given-names>PC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study</article-title>
          <source>Lancet Oncol</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>472</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="pmid">23598171</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Seto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Crino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>De Pas</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Besse</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Blackhall</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O'Byrne</surname>
              <given-names>KJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <fpage>2385</fpage>
          <lpage>2394</lpage>
          <pub-id pub-id-type="pmid">23724913</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Mehra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Felip</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>LQ</given-names>
            </name>
            <name>
              <surname>Camidge</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Vansteenkiste</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>De Pas</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Riely</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ceritinib in ALK-rearranged non-small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <fpage>1189</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="pmid">24670165</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance</article-title>
          <source>Acta Pharmaceutica Sinica B</source>
          <year>2015</year>
          <volume>5</volume>
          <fpage>34</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">26579422</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Konagai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fushiki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kondoh</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shindou</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Soga</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sakagami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Furutani</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Doihara</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice</article-title>
          <source>Mol Cancer Ther</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>329</fpage>
          <lpage>340</lpage>
          <pub-id pub-id-type="pmid">24419060</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ono</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wakuda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taira</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kenmotsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Naito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohde</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Endo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>P6.01 Dramatic response to ASP-3026 in patient with highly aggressive pulmonary inflammatory myofibroblastic tumor harboring ALK rearrangement</article-title>
          <source>Ann Oncol</source>
          <year>2015</year>
          <volume>26</volume>
          <fpage>ii28</fpage>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farina</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stasia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gambacorti Passerini</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase</article-title>
          <source>Blood Lymphat Cancer</source>
          <year>2014</year>
          <volume>4</volume>
          <fpage>69</fpage>
          <lpage>79</lpage>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vijayvergia</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mehra</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer</article-title>
          <source>Cancer Chemoth Pharm</source>
          <year>2014</year>
          <volume>74</volume>
          <fpage>437</fpage>
          <lpage>446</lpage>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amin</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Rajan</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Pongtornpipat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Groysman</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Tapia</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Cuyugan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Adkins</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rimsza</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Lussier</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Puvvada</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Schatz</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Evidence Suggesting that Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors</article-title>
          <source>Cancer Res</source>
          <year>2015</year>
          <volume>75</volume>
          <fpage>2916</fpage>
          <lpage>2927</lpage>
          <pub-id pub-id-type="pmid">26018086</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Algate</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Steelman</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Mayo</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Miyajima</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McCubrey</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Regulation of the interleukin-3 (IL-3) receptor by IL-3 in the fetal liver-derived FL5.12 cell line</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>83</volume>
          <fpage>2459</fpage>
          <lpage>2468</lpage>
          <pub-id pub-id-type="pmid">8167335</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Organ</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Tsao</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>An overview of the c-MET signaling pathway</article-title>
          <source>Ther Adv Med Oncol</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>S7</fpage>
          <lpage>S19</lpage>
          <pub-id pub-id-type="pmid">22128289</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiarle</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dhall</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zamo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karras</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Inghirami</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target</article-title>
          <source>Nat Med</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>623</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="pmid">15895073</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crescenzo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Abate</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lasorsa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tabbo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gaudiano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chiesa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Di Giacomo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Spaccarotella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barbarossa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ercole</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Todaro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Acquaviva</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma</article-title>
          <source>Cancer cell</source>
          <year>2015</year>
          <volume>27</volume>
          <fpage>516</fpage>
          <lpage>532</lpage>
          <pub-id pub-id-type="pmid">25873174</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Keats</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ning</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wardwell</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mohemmad</surname>
              <given-names>QK</given-names>
            </name>
            <name>
              <surname>Anjum</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Narasimhan</surname>
              <given-names>NI</given-names>
            </name>
            <name>
              <surname>Dalgarno</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shakespeare</surname>
              <given-names>WC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen</article-title>
          <source>Chem Biol Drug Des</source>
          <year>2011</year>
          <volume>78</volume>
          <fpage>999</fpage>
          <lpage>1005</lpage>
          <pub-id pub-id-type="pmid">22034911</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bresler</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Weiser</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Huwe</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Krytska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ryles</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Laudenslager</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rappaport</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>McGrady</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Hogarty</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>London</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Radhakrishnan</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma</article-title>
          <source>Cancer cell</source>
          <year>2014</year>
          <volume>26</volume>
          <fpage>682</fpage>
          <lpage>694</lpage>
          <pub-id pub-id-type="pmid">25517749</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ou</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Klempner</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Greenbowe</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Azada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schrock</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>VA</given-names>
            </name>
          </person-group>
          <article-title>Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib</article-title>
          <source>J Thorac Oncol</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>1821</fpage>
          <lpage>1825</lpage>
          <pub-id pub-id-type="pmid">25393796</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mologni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ceccon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pirola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chiriano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Piazza</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Scapozza</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922</article-title>
          <source>Oncotarget</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>5720</fpage>
          <lpage>5734</lpage>
          <pub-id pub-id-type="doi">10.18632/oncotarget.3122</pub-id>
          <pub-id pub-id-type="pmid">25749034</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Friboulet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Leshchiner</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gainor</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Bergqvist</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brooun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dardaei</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Frias</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Logan</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F</article-title>
          <source>New Engl J Med</source>
          <year>2016</year>
          <volume>374</volume>
          <fpage>54</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">26698910</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ceccon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mologni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bisson</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Scapozza</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors</article-title>
          <source>Mol Cancer Res</source>
          <year>2013</year>
          <volume>11</volume>
          <fpage>122</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">23239810</pub-id>
        </element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Vishwamitra</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Manshouri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Amin</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma <italic>in vitro</italic> and in a systemic xenograft lymphoma model</article-title>
          <source>Oncotarget</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>5750</fpage>
          <lpage>5763</lpage>
          <pub-id pub-id-type="doi">10.18632/oncotarget.2170</pub-id>
          <pub-id pub-id-type="pmid">25026277</pub-id>
        </element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katayama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Friboulet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Koike</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lockerman</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Gainor</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Iafrate</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taiji</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okuno</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Engelman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib</article-title>
          <source>Clin Cancer Res</source>
          <year>2014</year>
          <volume>20</volume>
          <fpage>5686</fpage>
          <lpage>5696</lpage>
          <pub-id pub-id-type="pmid">25228534</pub-id>
        </element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ou</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Greenbowe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>ZU</given-names>
            </name>
            <name>
              <surname>Azada</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Gitlitz</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib</article-title>
          <source>Lung cancer</source>
          <year>2015</year>
          <volume>88</volume>
          <fpage>231</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="pmid">25736571</pub-id>
        </element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toyokawa</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Inamasu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nosaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takenaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takenoyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ichinose</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib</article-title>
          <source>J Thorac Oncol</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>e86</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">25393798</pub-id>
        </element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zdzalik</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dymek</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Grygielewicz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gunerka</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bujak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lamparska-Przybysz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wieczorek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dzwonek</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma</article-title>
          <source>J Cancer Res Clin Oncol</source>
          <year>2014</year>
          <volume>140</volume>
          <fpage>589</fpage>
          <lpage>598</lpage>
          <pub-id pub-id-type="pmid">24509625</pub-id>
        </element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Friboulet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Katayama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Gainor</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Michellys</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Awad</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Yanagitani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pferdekamper</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kasibhatla</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer</article-title>
          <source>Cancer Discov</source>
          <year>2014</year>
          <volume>4</volume>
          <fpage>662</fpage>
          <lpage>673</lpage>
          <pub-id pub-id-type="pmid">24675041</pub-id>
        </element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ni</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer</article-title>
          <source>J Mol Model</source>
          <year>2015</year>
          <volume>21</volume>
          <fpage>2716</fpage>
        </element-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bossi</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Saccardo</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Ardini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Menichincheri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rusconi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Magnaghi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Orsini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Avanzi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Borgia</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Nesi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bandiera</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fogliatto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bertrand</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors</article-title>
          <source>Biochemistry</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>6813</fpage>
          <lpage>6825</lpage>
          <pub-id pub-id-type="pmid">20695522</pub-id>
        </element-citation>
      </ref>
      <ref id="R50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cui</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Tran-Dube</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nambu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kung</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Pairish</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Funk</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Botrous</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>McTigue</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grodsky</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</article-title>
          <source>J Med Chem</source>
          <year>2011</year>
          <volume>54</volume>
          <fpage>6342</fpage>
          <lpage>6363</lpage>
          <pub-id pub-id-type="pmid">21812414</pub-id>
        </element-citation>
      </ref>
      <ref id="R51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kornev</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Haste</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Eyck</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>17783</fpage>
          <lpage>17788</lpage>
          <pub-id pub-id-type="pmid">17095602</pub-id>
        </element-citation>
      </ref>
      <ref id="R52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kornev</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Ten Eyck</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>A helix scaffold for the assembly of active protein kinases</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2008</year>
          <volume>105</volume>
          <fpage>14377</fpage>
          <lpage>14382</lpage>
          <pub-id pub-id-type="pmid">18787129</pub-id>
        </element-citation>
      </ref>
      <ref id="R53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Infarinato</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Krytska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ryles</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Szigety</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Smeal</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lemmon</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Mosse</surname>
              <given-names>YP</given-names>
            </name>
          </person-group>
          <article-title>The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma</article-title>
          <source>Cancer Discov</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>96</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="pmid">26554404</pub-id>
        </element-citation>
      </ref>
      <ref id="R54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bresler</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Haglund</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Courtright</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Belcastro</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Plegaria</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Toporovskaya</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Maris</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Lemmon</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma</article-title>
          <source>Sci Transl Med</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>108ra114</fpage>
        </element-citation>
      </ref>
      <ref id="R55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heuckmann</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holzel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sos</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Heynck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Balke-Want</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Koker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peifer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lovly</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Grutter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rauh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>ALK mutations conferring differential resistance to structurally diverse ALK inhibitors</article-title>
          <source>Clin Cancer Res</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>7394</fpage>
          <lpage>7401</lpage>
          <pub-id pub-id-type="pmid">21948233</pub-id>
        </element-citation>
      </ref>
      <ref id="R56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sasaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Okuda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Butrynski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Capelletti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Wilner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Demetri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Rodig</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Eck</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers</article-title>
          <source>Cancer Res</source>
          <year>2010</year>
          <volume>70</volume>
          <fpage>10038</fpage>
          <lpage>10043</lpage>
          <pub-id pub-id-type="pmid">21030459</pub-id>
        </element-citation>
      </ref>
      <ref id="R57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sasaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Koivunen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ogino</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yanagita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nikiforow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lathan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marcoux</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Okuda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Capelletti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ercan</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</article-title>
          <source>Cancer Res</source>
          <year>2011</year>
          <volume>71</volume>
          <fpage>6051</fpage>
          <lpage>6060</lpage>
          <pub-id pub-id-type="pmid">21791641</pub-id>
        </element-citation>
      </ref>
      <ref id="R58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kodama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsukaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kondoh</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance</article-title>
          <source>Cancer Lett</source>
          <year>2014</year>
          <volume>351</volume>
          <fpage>215</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="pmid">24887559</pub-id>
        </element-citation>
      </ref>
      <ref id="R59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ignatius Ou</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Azada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hsiang</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kain</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Siwak-Tapp</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Casey</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Klempner</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>VA</given-names>
            </name>
          </person-group>
          <article-title>Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib</article-title>
          <source>J Thorac Oncol</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>549</fpage>
          <lpage>553</lpage>
          <pub-id pub-id-type="pmid">24736079</pub-id>
        </element-citation>
      </ref>
      <ref id="R60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ceccon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mologni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Giudici</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Piazza</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pirola</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fontana</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma</article-title>
          <source>Mol Cancer Res</source>
          <year>2015</year>
          <volume>13</volume>
          <fpage>775</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="pmid">25421750</pub-id>
        </element-citation>
      </ref>
      <ref id="R61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katayama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Mino-Kenudson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Halmos</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jessop</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Wain</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Yeo</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Benes</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Drew</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Saeh</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Crosby</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</article-title>
          <source>Sci Transl Med</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>120ra117</fpage>
        </element-citation>
      </ref>
      <ref id="R62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chand</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ruuth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schonherr</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Martinsson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kogner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Attiyeh</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Maris</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Morozova</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Marra</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ohira</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakagawara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sandstrom</surname>
              <given-names>PE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma</article-title>
          <source>Dis Model Mech</source>
          <year>2013</year>
          <volume>6</volume>
          <fpage>373</fpage>
          <lpage>382</lpage>
          <pub-id pub-id-type="pmid">23104988</pub-id>
        </element-citation>
      </ref>
      <ref id="R63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doebele</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Pilling</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Aisner</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Kutateladze</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Weickhardt</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Linderman</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Heasley</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Franklin</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Varella-Garcia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Camidge</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer</article-title>
          <source>Clin Cancer Res</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>1472</fpage>
          <lpage>1482</lpage>
          <pub-id pub-id-type="pmid">22235099</pub-id>
        </element-citation>
      </ref>
      <ref id="R64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fontana</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ceccon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mologni</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK</article-title>
          <source>Cancer Med</source>
          <year>2015</year>
          <volume>4</volume>
          <fpage>953</fpage>
          <lpage>965</lpage>
          <pub-id pub-id-type="pmid">25727400</pub-id>
        </element-citation>
      </ref>
      <ref id="R65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brooun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bunker</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Dack</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Deal</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Dinh</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib</article-title>
          <source>J Med Chem</source>
          <year>2014</year>
          <volume>57</volume>
          <fpage>1170</fpage>
          <lpage>1187</lpage>
          <pub-id pub-id-type="pmid">24432909</pub-id>
        </element-citation>
      </ref>
      <ref id="R66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshimura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kurasawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yorozu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Puig</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bordogna</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Harada</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells</article-title>
          <source>Cancer Chemother Pharmacol</source>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="R67">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brooun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Deal</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Dinh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Engstrom</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</article-title>
          <source>J Med Chem</source>
          <year>2014</year>
          <volume>57</volume>
          <fpage>4720</fpage>
          <lpage>4744</lpage>
          <pub-id pub-id-type="pmid">24819116</pub-id>
        </element-citation>
      </ref>
      <ref id="R68">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zou</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Friboulet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kodack</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Engstrom</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsaparikos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Timofeevski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Katayama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dinh</surname>
              <given-names>DM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</article-title>
          <source>Cancer cell</source>
          <year>2015</year>
          <volume>28</volume>
          <fpage>70</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">26144315</pub-id>
        </element-citation>
      </ref>
      <ref id="R69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hatcher</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bahcall</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sim</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Janne</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <article-title>Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation</article-title>
          <source>J Med Chem</source>
          <year>2015</year>
          <volume>58</volume>
          <fpage>9296</fpage>
          <lpage>9308</lpage>
          <pub-id pub-id-type="pmid">26568289</pub-id>
        </element-citation>
      </ref>
      <ref id="R70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sch&#xF6;nherr</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ruuth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hallberg</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684</article-title>
          <source>Biochem J</source>
          <year>2011</year>
          <volume>440</volume>
          <fpage>405</fpage>
          <lpage>413</lpage>
          <pub-id pub-id-type="pmid">21838707</pub-id>
        </element-citation>
      </ref>
      <ref id="R71">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsukaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hiroshima</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kodama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fukami</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Oikawa</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tsukuda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</article-title>
          <source>Cancer cell</source>
          <year>2011</year>
          <volume>19</volume>
          <fpage>679</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="pmid">21575866</pub-id>
        </element-citation>
      </ref>
      <ref id="R72">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Car&#xE9;n</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Abel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kogner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martinsson</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours</article-title>
          <source>Biochem J</source>
          <year>2008</year>
          <volume>416</volume>
          <fpage>153</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="pmid">18990089</pub-id>
        </element-citation>
      </ref>
      <ref id="R73">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinsson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Abrahamsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caren</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hansson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kogner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kamaraj</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schonherr</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weinmar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ruuth</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hallberg</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy</article-title>
          <source>Cancer Res</source>
          <year>2011</year>
          <volume>71</volume>
          <fpage>98</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="pmid">21059859</pub-id>
        </element-citation>
      </ref>
      <ref id="R74">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McDuff</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Dalbay</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants</article-title>
          <source>Mol Carcinog</source>
          <year>2013</year>
          <volume>52</volume>
          <fpage>79</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">22086496</pub-id>
        </element-citation>
      </ref>
      <ref id="R75">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourdeaut</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ferrand</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brugieres</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hilbert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lacroix</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Benard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Combaret</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Michon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Valteau-Couanet</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Isidor</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rialland</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Poiree</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome</article-title>
          <source>Eur J Human Genet</source>
          <year>2012</year>
          <volume>20</volume>
          <fpage>291</fpage>
          <lpage>297</lpage>
          <pub-id pub-id-type="pmid">22071890</pub-id>
        </element-citation>
      </ref>
      <ref id="R76">
        <label>76</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kodama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsukaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kondoh</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer</article-title>
          <source>Mol Cancer Ther</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>2910</fpage>
          <lpage>2918</lpage>
          <pub-id pub-id-type="pmid">25349307</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>